Ghasemzadeh Rahbardar, and H
To compare telehealth providers offering compounded semaglutide and tirzepatide, see our 2026 GLP-1 telehealth programs comparison.
Semaglutide, a leading GLP-1 receptor agonist, demonstrated a mean weight loss of 14.9% at weekly doses of 2.4 mg, compared with only 2.4% for placebo

Putting This Into Practice Keep a detailed menstrual calendar starting before semaglutide treatment to establish baseline patterns Weigh yourself weekly rather than daily to track overall trends without fixating on fluctuations Calculate your rate of weight loss monthly and note any correlation with cycle changes Maintain adequate protein intake and consider nutrition counseling if experiencing rapid weight loss Schedule follow-up appointments every 3 months to discuss menstrual changes with your healthcare provider When to Seek Professional Help Absence of periods for more than three consecutive months Heavy bleeding soaking through one pad or tampon hourly for several hours Bleeding lasting longer than seven days Severe pelvic pain accompanying menstrual changes Positive pregnancy test while taking semaglutide New onset of hot flashes or other menopausal symptoms in premenopausal women Breakthrough bleeding occurring more than once per cycle Return of PCOS symptoms after initial improvement Commonly Asked Questions Can I continue semaglutide if my periods stop

Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen Summary of Product Characteristics
[DOI] [PubMed] [Google Scholar] 76.Boban-Blagaic A., Blagaic V., Romic Z., Sikiric P